secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2023-03-03T23:59:59+00:00
Accession:  0001213900-23-016996
Event type: regulatory
Sentiment:  neutral
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix updates DefenCath NDA resubmission pathways; CMO 1 completes corrective actions
--------------------------------------------------------------------------------

- CMO 1 completed all corrective actions from FDA's June 2022 inspection; awaits FDA feedback on compliance status.
- Heparin API supplier updated DMF; FDA recently approved a supplement referencing same DMF, potentially removing warning letter barrier.
- Company plans to submit Type A meeting request by mid-March to seek FDA guidance on CMO 1 clearance and API 1 DMF use.
- Pathway #1 (CMO 1 + API 1) could be Class 1 (60-day review); Pathway #2 (CMO 1 + API 2) data expected mid-April, Class 2 (6-month).
- Pathway #3 (CMO 2 + API 2) data delayed to Q3 2023; remains backup strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023016996/0001213900-23-016996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023016996/ea174602-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-016996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer